Central and regional hemodynamic effects during infusion of Big endothelin-1 in healthy humans

Journal of Applied Physiology

Volumn 80, Issue 6, 1996, Pages 1921-1927

  Ahlborg, Gunvor ^a   Ottosson Seeberger, Astrid ^b   Hemsén, Anette ^b   Lundberg, Jan M ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

cerebral Big endothelin 1 and endothelin 1 exchange; pulmonary Big endothelin 1 and endothelin 1 exchange; pulmonary vascular resistance; receptor binding; skeletal muscle Big endothelin 1 and endothelin 1 exchange; systemic vascular resistance

Indexed keywords

BIG ENDOTHELIN 1; BOSENTAN;

ADULT; ARTERIAL OXYGEN TENSION; ARTERIAL PH; ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; FOREARM BLOOD FLOW; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTENSION; INTERNAL JUGULAR VEIN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SYSTEMIC VASCULAR RESISTANCE;

EID: 0030054840     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1996.80.6.1921     Document Type: Article

References (30)

1. Ahlborg, G., A. Ottosson-Seeberger, A. Hemsén, and J. M. Lundberg. Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction and increased mean arterial blood pressure. Cardiovasc. Res. 28: 1559-1563, 1994.
2. Ahlborg, G., E. Weitzberg, A. Sollevi, and J. M. Lundberg. Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man. Acta Physiol. Scand. 145: 139-149, 1992.
3. Clozel, M., V. Breu, G. A. Gray, B. Kalina, B.-M. Löffler, K. Burri, J. M. Cassai, G. Hirth, M. Müller, W. Neidhart, and H. Ramuz. Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270: 228-235, 1994.
4. Goetz, K. L., B. C. Wang, J. B. Madwed, J. L. Zhu, and R. J. Leadley, Jr.. Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. Am. J. Physiol. 255 (Regulatory Integrative Comp. Physiol. 24): R1064-R1068, 1988.
5. Graf, K., and A. Westersten. Untersuchungen über Eigenschaften und Verwendungsmöglichkeiten eines flexiblen Extremitätenplethysmografen. Acta Physiol. Scand. 46: 1-18, 1959.
6. Hemsén, A., G. Ahlborg, A. Ottosson-Seeberger, and J. M. Lundberg. Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21) Regul. Pept. 55: 287-297, 1995.
7. Hemsén, A., A. Franco-Cereceda, R. Matran, A. Rudehill, and J. M. Lundberg. Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur. J. Pharmacol. 191: 319-328, 1990.
8. Hemsén, A., O. Larsson, and J. M. Lundberg. Characteristics of endothelin-A and -B binding sites and their vascular effects in pig peripheral tissues. Eur. J. Pharmacol. 208: 313-322, 1991.
9. Hemsén, A., J. Pernow, and J. M. Lundberg. Regional extraction of endothelins and conversion of Big endothelin to endothelin-1 in the pig. Acta Physiol. Scand. 141: 325-334, 1991.
10. Hjemdahl, P. Catecholamine measurements in plasma by highperformance liquid chromatography with electrochemical detection. Methods Enzymol. 142: 521-534, 1987.
11. Kashiwabara, T., Y. Inagaki, H. Ohta, A. Iwamatsu, M. Nomizu, A. Monta, and K. Nishikori. Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett. 247: 73-76, 1989.
12. Koseki, C., M. Imai, Y. Hirata, M. Yanagisawa, and T. Masaki. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am. J. Physiol. 256 (Regulatory Integrative Comp. Physiol. 25): R858-R866, 1989.
13. Mima, T., M. Yanagisawa, T. Shigeno, A. Saito, K. Goto, K. Takakura, and T. Masaki. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 20: 1553-1556, 1989.
14. Miyauchi, T., M. Yanagisawa, T. Tomizawa, Y. Sugishita, N. Suzuki, M. Fujino, R. Ajisaka, K. Goto, and T. Masaki. Increased plasma concentrations of endothelin-1 and Big endothelin-1 in acute myocardial infarction. Lancet 2: 53-54, 1989.
15. Moore, F. D., K. H. Olesen, J. D. McMurrey, H. V. Parker, M. R. Ball, and C. M. Boyden. The Body Cell Mass and Its Supporting Environment. Philadelphia, PA: Saunders, 1963, p. 58-173.
16. Ohwaki, T., H. Sakai, and Y. Hirata. Endothelin-converting enzyme activity in human serum lipoprotein fraction. FEBS Lett. 320: 165-168, 1993.
17. Pernow, J., A. Hemsén, J. M. Lundberg, J. Nowak, and L. Kaijser. Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol. Scand. 141: 319-324, 1991.
18. Rubanyi, G. M., and M. A. Polokoff. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 46: 328-415, 1994.
19. Saito, Y., K. Nakao, M. Mukoyama, and H. Imura. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 322: 205, 1990.
20. Sawamura, T., S. Kimura, O. Shinmi, Y. Sugita, M. Yanagisawa, and T. Masaki. Analysis of endothelin related peptides in culture supernatant of porcine aortic cells: evidence for biosynthetic pathway of endothelin-1. Biochem. Biophys. Res. Commun. 162: 1287-1294, 1989.
21. Shinyama, H., T. Uchida, H. Kido, K. Hayashi, M. Watanabe, Y. Matsumara, R. Ikegawa, M. Takaoka, and S. Morimoto. Phosphoramidon inhibits the conversion of intracisternally administered Big endothelin-1 to endothelin-1. Biochem. Biophys. Res. Commun. 178: 24-30, 1991.
22. Stewart, D. J., P. Cernacek, K. B. Costello, and J. L. Rouleau. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85: 510-517, 1992.
23. Wagner, O. F., G. Christ, J. Wojta, H. Vierhapper, S. Parzer, P. J. Nowotny, B. Schneider, W. Waldhäusl, and B. R. Binder. Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem. 267: 16066-16068, 1992.
24. Warner, T. D., H. H. Schmidt, J. Kuk, J. A. Mitchell, and F. Murad. Human brain contains a metalloprotease that converts Big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA. Br. J. Pharmacol. 106: 505-506, 1992.
25. Weitzberg, E., G. Ahlborg, and J. M. Lundberg. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem. Biophys. Res. Commun. 180: 1298-1303, 1991.
26. Weitzberg, E., G. Ahlborg, and J. M. Lundberg. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin. Physiol. Oxf. 13: 653-662, 1993.
27. Willette, R. N., C. Sauermelch, M. Ezekiel, G. Feuerstein, and E. H. Ohlstein. Effect of endothelin on cortical microvascular perfusion in rats. Stroke 21: 451-458, 1990.
28. Winer, B. J. Statistical Principles in Experimental Design. New York: McGraw-Hill, 1971, p. 199.
29. Xu, D., N. Emoto, A. Giaid, C. Slaughter, S. Kaw, D. de Wit, and M. Yanagisawa. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of Big endothelin-1. Cell 78: 473-485, 1994.
30. Yanagisawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature Lond. 332: 411-415, 1988.